Valeant Pharma (VRX) Bounces Modestly Off Lows Following Ackman Letter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Ackman Said to Add to Valeant Pharma (VRX) Stake - Chatter
March 15, 2016 3:58 PM EDTPershing Square's Bill Ackman is adding to his stake in Valeant Pharma (NYSE: VRX) amid today's sell-off, according to unconfirmed market chatter.... More
Deutsche Bank Comments on Valeant Pharma (VRX) Following Q4 Call
March 15, 2016 2:20 PM EDTDeutsche Bank analyst Gregg Gilbert commented on Valeant Pharma (NYSE: VRX) after it released Q4 earnings and discussed challenges on its conference call. The analyst noted operational challenges and overhang from its 10-K delay.
"The new 2016 guidance reflects in large part lower growth assumptions for the core US business (including Dermatology and GI) without offsetting cost reductions (which the company will explore). On the positive side, VRX described making progress with payors, and cited greater visibility on managed... More
Ackman's Pershing Square Sends Letter to Investors Following Valeant's (VRX) Q4 Report, Updated Outlook
March 15, 2016 12:15 PM EDTRegulatory News:
Pershing Square Holdings, Ltd. today released an email to investors. The text of the email is set forth below:
Dear Pershing Square Investor,
Today, Valeant (NYSE: VRX) reported preliminary unaudited earnings for Q4, updated guidance for Q1, full year 2016 and the next twelve months. In particular, management shocked the market with revenue and earnings... More
